1980-Present

  • Follow Us:

Learn about Stiefel through the years.  

1980’s – 1990’s: International Growth

Stiefel Laboratories began the 1980s with six subsidiaries in major markets and many distributors. During the decade, 17 new subsidiaries were opened. Stiefel Laboratories’ first R&D facility outside of the U.S. was established in 1985 in Slough, a city near the company’s United Kingdom headquarters. (It was later moved to Maidenhead.) Another R&D facility was established in Brazil. At the close of the 1980s, international sales had grown to nearly $50 million. The company’s operations continued to expand and by the 1990s, Stiefel Laboratories boasted subsidiaries in more than 30 countries and relationships with distributors in 70 others. By the end of the decade, factories were operating in Ireland, Brazil, Singapore, and Mexico, supplying markets around the world. Sales had reached $180 million.

1991: Glades Pharmaceuticals


Stiefel Laboratories founded Glades Pharmaceuticals to market generic dermatology products. Glades Pharmaceuticals later matured to market a full line of products including branded-generic and branded products. Brevoxyl®/Solugel® Creamy Wash was launched as the first benzoyl peroxide product containing dimethyl isosorbide to dissolve the benzoyl peroxide crystals and help reduce skin irritation.

1992:

Stiefel Laboratories introduced Isotrex® Gel as the world's first topical isotretinoin product.

2000:

Stiefel Laboratories introduced Physiogel®—a brand of skin care products that was the first family of "skin repair" products based on natural lipid, emulsifier-free repair technology.

2002:

Stiefel Laboratories was the first to market a combination of benzoyl peroxide and clindamycin for acne treatment. Stiefel Laboratories also established the Versafoam® brand.

2006:

Stiefel Laboratories made its first major corporate acquisition when it acquired California-based Connetics Corporation, a specialty pharmaceutical company focused on the development and commercialisation of innovative therapeutics for the dermatology market.

2007:

Stiefel Laboratories introduced REVALÉSKIN®, the first and only professional line of anti-aging skin care products exclusively formulated with the powerful natural antioxidant ingredient, CoffeeBerry® extract.

2008:

Stiefel Laboratories announced the promotion of William D. (Bill) Humphries to president of the privately-held dermatology company. Stiefel Laboratories completed the acquisition of Barrier Therapeutics, Inc. (“Barrier Therapeutics”) on August 6, 2008.

2009:

Stiefel Laboratories launched Impruv® Dry Skin Product for its consumer product portfolio.

2009:

GlaxoSmithKline completed the acquisition of Stiefel Laboratories, Inc. and announced that the new dermatology unit within GSK will operate under the name Stiefel, a GSK company.

2010:

Stiefel launched The MaxClarity™ System, to bring acne innovation directly to consumers. The MaxClarity™ System uses VersaFoam® technology, which allows benzoyl peroxide and salicylic acid to penetrate the skin quickly and fight acne at the source before it becomes a pimple.

2010:

Stiefel received FDA approval for in the United States—VELTIN™ (clindamycin phosphate and tretinoin) Gel, 1.2%/0.025% , a topical acne treatment.

2011:

Stiefel launched PanOxyl®, an over-the-counter formulation of the most-prescribed benzoyl peroxide acne wash.

2012:

Stiefel and ILDS announce completion of first year of Hats on for Skin Health Campaign

2012:

Stiefel receives US FDA approval of Fabior™ (tazarotene) Foam, 0.1%, a topical foam formulation for the treatment of acne vulgaris in patients 12 years of age and older.

2012:

Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis, currently in Phase II clinical development.

2012:

Stiefel signs worldwide acquisition and license agreement for Toctino®, a once-daily oral retinoid approved for the treatment of severe chronic hand eczema unresponsive to potent topical steroids in adults in 29 countries. Toctino is in a phase three trial in the United States.